David A. Siegel Editas Medicine, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,234,300 shares of EDIT stock, worth $5.76 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,234,300
Previous 1,141,500
8.13%
Holding current value
$5.76 Million
Previous $11.6 Million
20.8%
% of portfolio
0.02%
Previous 0.03%
Shares
26 transactions
Others Institutions Holding EDIT
# of Institutions
243Shares Held
69.3MCall Options Held
564KPut Options Held
428K-
State Street Corp Boston, MA8.76MShares$40.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.56MShares$40 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.83MShares$36.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.53MShares$25.8 Million1.35% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.61MShares$12.2 Million0.01% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $321M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...